List of Excipients in Branded Drug OTREXUP

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Antares Pharma Inc	OTREXUP	methotrexate	54436-075	SODIUM CHLORIDE	2030-03-19
Antares Pharma Inc	OTREXUP	methotrexate	54436-075	WATER	2030-03-19
Otter Pharmaceuticals LLC	OTREXUP	methotrexate	82497-010	SODIUM CHLORIDE	2030-03-19
Otter Pharmaceuticals LLC	OTREXUP	methotrexate	82497-010	WATER	2030-03-19

Otrexup Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Otrexup is a preservative-free, single-dose subcutaneous methotrexate autoinjector approved by the FDA for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe psoriasis. Its excipient system is intentionally simple: water for injection, sodium chloride, sodium hydroxide, and hydrochloric acid. Commercial value is concentrated in the device, dose presentation, usability, and differentiated delivery system rather than in a novel excipient platform.[1]

The main opportunity for competitors is to develop a comparable methotrexate autoinjector with equivalent or improved human-factors performance. Excipient reformulation alone is unlikely to create substantial differentiation unless it supports a lower injection volume, improved chemical stability, reduced pain, longer shelf life, or compatibility with a new delivery device.

What is Otrexup and how is its formulation designed?

Otrexup is a single-dose, disposable autoinjector containing methotrexate for subcutaneous administration. The product is supplied in four dose strengths: 10 mg, 15 mg, 20 mg, and 25 mg.[1]

Product attribute	Otrexup profile
Active ingredient	Methotrexate
Dosage form	Single-dose subcutaneous injection
Delivery system	Disposable autoinjector
Approved strengths	10, 15, 20, and 25 mg
Primary indications	Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, severe psoriasis
Preservative	None identified in the FDA label
Surfactant	None identified in the FDA label
Antioxidant	None identified in the FDA label
Buffering agents	Hydrochloric acid and sodium hydroxide for pH adjustment
Tonicity agent	Sodium chloride
Vehicle	Water for injection
FDA approval	NDA 204824, approved October 11, 2013

The formulation uses a low-complexity aqueous system. Sodium chloride adjusts osmolality, while hydrochloric acid and sodium hydroxide control pH. This design reduces excipient-related regulatory and manufacturing burdens, but it also limits opportunities to claim a novel composition of matter.

What excipients does Otrexup contain?

The Otrexup label identifies sodium chloride, sodium hydroxide, hydrochloric acid, and water for injection as inactive ingredients.[1] The formulation does not depend on a preservative, cosolvent, surfactant, chelating agent, or amino-acid stabilizer.

That profile has several commercial consequences:

1. The product avoids preservative exposure in a single-dose presentation.
2. The formulation is suitable for a compact, ready-to-use delivery system.
3. The absence of surfactants reduces the risk of device-material compatibility issues.
4. The formulation can be manufactured using conventional sterile aqueous-injection processes.
5. The limited excipient set leaves little room for meaningful formulation differentiation.

The commercial moat is therefore based primarily on the autoinjector and product configuration.

How does Otrexup’s excipient strategy compare with competing methotrexate products?

Otrexup competes with injectable methotrexate products supplied in vials, prefilled syringes, and autoinjectors. Rasuvo, marketed by Medac, is the closest branded device competitor. Generic methotrexate injection products generally compete on price but require patients or caregivers to draw doses from vials or use conventional syringes.

Product	Delivery format	Excipient strategy	Commercial differentiation
Otrexup	Disposable autoinjector	Simple aqueous, preservative-free formulation	Device convenience and fixed-dose delivery
Rasuvo	Disposable autoinjector	Aqueous methotrexate formulation	Autoinjector and dose selection
Generic methotrexate injection	Vial or conventional injection	Typically simple aqueous formulation	Low acquisition cost
Methotrexate prefilled syringe products	Prefilled syringe	Aqueous injectable formulation	Reduced preparation burden
Xatmep	Oral solution	Oral liquid excipient system	Alternative route for selected patients

The principal distinction between Otrexup and generic methotrexate injection is administration convenience. A generic vial may contain the same active ingredient and similar basic excipients, but it does not necessarily provide the same patient experience or device functionality.

Is Otrexup’s formulation protected by excipient patents?

The FDA label does not indicate a proprietary excipient with independent commercial significance. Any meaningful formulation protection would more likely arise from the combination of methotrexate concentration, pH, container closure, device compatibility, sterility controls, and delivery configuration.

For a follow-on product, the most relevant technical questions are whether the proposed formulation:

• Maintains methotrexate stability through the labeled shelf life;
• Remains compatible with the autoinjector reservoir, needle, elastomer, and internal lubricants;
• Meets particulate and extractables-and-leachables limits;
• Delivers the labeled dose across the full temperature range;
• Avoids crystallization or precipitation;
• Produces acceptable injection force and completion time;
• Provides equivalent or superior usability for patients with rheumatoid arthritis.

An excipient change that does not improve one of these attributes is unlikely to support a durable commercial position.

What formulation opportunities exist for Otrexup competitors?

The strongest formulation opportunities are incremental. They involve improving the interaction between the formulation and the delivery system rather than introducing a radically different excipient package.

Lower-volume methotrexate presentations

A higher-concentration formulation could reduce injection volume and potentially improve patient comfort. The opportunity is technically constrained by methotrexate solubility, pH, local tolerability, viscosity, and dose accuracy.

A lower-volume product could support:

• Smaller autoinjectors;
• Shorter injection times;
• Reduced packaging volume;
• Lower shipping and storage costs;
• Easier administration for patients with limited dexterity.

The risk is that increasing concentration may require pH adjustment, a different buffer system, or additional solubilization support. Those changes can create local tolerability and stability issues.

Pain-reduction formulations

Methotrexate injections may produce local discomfort. A competitor could evaluate pH, osmolality, ionic strength, injection volume, and injection speed as a combined pain-reduction strategy.

The practical commercial value would depend on controlled clinical and human-factors evidence. A small change in sodium chloride concentration or pH is unlikely to create a defensible position by itself. A formulation-device combination that demonstrates lower injection pain could be more valuable.

Device-compatible stabilizer systems

Methotrexate stability can be evaluated with selected buffering, chelating, or antioxidant approaches. These excipients could create new compatibility burdens, particularly in a small-volume autoinjector.

Any stabilizer strategy would need to address:

• Oxidative degradation;
• Light sensitivity;
• Interaction with metals or device components;
• Container closure adsorption;
• Subvisible particles;
• Sterilization and aseptic processing;
• Long-term storage at refrigerated and room temperatures.

A new excipient would also increase regulatory exposure if it lacks established precedent in subcutaneous methotrexate products.

Improved cold-chain flexibility

A formulation that tolerates wider temperature excursions could reduce distribution losses and simplify pharmacy handling. This opportunity has commercial value in specialty pharmacy channels, where product replacement and shipment management affect net margins.

The product would need real-time and accelerated stability data supporting the proposed storage conditions. A shelf-life extension alone is unlikely to overcome a weak device proposition, but it can improve supply-chain economics.

What FDA regulatory pathway applies to an Otrexup follow-on product?

A follow-on product may use an abbreviated new drug application if it can demonstrate the required equivalence to the reference product and meet applicable device requirements. A materially different device, concentration, indication, or clinical use may require a 505(b)(2) application.

The regulatory assessment depends on the proposed product:

Proposed change	Likely regulatory issue
Same methotrexate strength and dosage form in a comparable device	ANDA or other abbreviated pathway may be available
New autoinjector with different operating characteristics	Device equivalence and human-factors evidence
Higher methotrexate concentration	New formulation and clinical tolerability risk
New excipient	Safety, compatibility, and stability justification
New route of administration	Likely 505(b)(2) or full development pathway
New indication	Method-of-use and clinical evidence issues
New dosing flexibility	Labeling, device, and dose-delivery validation

A generic vial is not automatically substitutable for an autoinjector presentation from a patient or commercial perspective. Pharmacy substitution depends on the approved product classification, labeling, state law, payer policy, and product-specific FDA determinations.

What is the FDA exclusivity status of Otrexup?

Otrexup received three-year new-drug exclusivity associated with its approval as a new dosage form and delivery presentation. That exclusivity period would have expired in 2016.[1] Otrexup is not an orphan drug for its principal approved indications.

The commercial question is therefore patent and device protection, not remaining FDA market exclusivity.

What patents protect Otrexup and its delivery system?

Otrexup protection has historically centered on Antares Pharma’s injection-device technology and related drug-delivery patents. The relevant intellectual-property categories include:

• Autoinjector architecture;
• Needle deployment and retraction;
• Dose delivery mechanics;
• Container and cartridge integration;
• Device activation;
• Formulation-device compatibility;
• Methods of subcutaneous methotrexate administration.

The active ingredient, methotrexate, is an old compound and does not provide meaningful composition-of-matter exclusivity. The commercial protection therefore depends on device claims, formulation claims, method-of-use claims, and regulatory exclusivity.

What is the Orange Book status of Otrexup?

Otrexup is approved under NDA 204824. The FDA Orange Book is the controlling public record for listed patents and regulatory exclusivity associated with that NDA.[2]

A competitor evaluating an Otrexup launch must separate three issues:

1. Whether a patent is listed against NDA 204824;
2. Whether the patent claims cover the proposed product;
3. Whether the patent remains enforceable and unexpired at the expected launch date.

Device patents may not block a product that uses a materially different autoinjector architecture. Conversely, a product that avoids the exact Otrexup formulation may still face device patent risk if it uses similar mechanisms.

When does Otrexup lose exclusivity, and what generic entry risks exist?

Regulatory exclusivity has already expired. Generic entry risk is therefore determined by patents, development cost, device complexity, and payer acceptance.

Paragraph IV challenges

A Paragraph IV filing could challenge listed patents by asserting that they are invalid, unenforceable, or not infringed. The most commercially relevant challenge would likely target device or formulation claims rather than methotrexate itself.

A generic sponsor could pursue one of several strategies:

• Use a conventional vial and compete on price;
• Develop a prefilled syringe;
• Build a non-infringing autoinjector;
• File an ANDA with a device that satisfies FDA substitutability requirements;
• Pursue a 505(b)(2) product with a differentiated injector or concentration;
• Challenge method-of-use claims through a skinny label.

Generic launch scenarios

Scenario	Commercial effect
Low-cost vial entry	Price pressure on methotrexate but limited direct substitution
Prefilled syringe entry	Greater convenience competition and payer leverage
Autoinjector ANDA entry	Direct pressure on Otrexup pricing and access
505(b)(2) differentiated device	Potential premium positioning with higher development cost
Patent settlement with delayed entry	Preserves branded pricing for a defined period
Device patent litigation	Can delay, redirect, or increase the cost of launch

The most credible near-term threat is not necessarily a chemically identical generic. It is a comparable self-injection product with a lower net price and similar usability.

Which companies are positioned to challenge Otrexup?

The competitive field includes generic injectable manufacturers, specialty pharmaceutical companies, and device developers with experience in self-administered products.

Potential competitor categories include:

• Large generic manufacturers with sterile injectable capacity;
• Specialty companies selling rheumatoid arthritis therapies;
• Methotrexate suppliers with prefilled syringe platforms;
• Autoinjector manufacturers licensing device technology;
• 505(b)(2) developers targeting adherence and administration convenience.

Medac’s Rasuvo is the most direct branded comparator. Conventional methotrexate injection manufacturers create price competition, although their products generally lack the same integrated autoinjector experience.

How strong is the Otrexup patent estate?

Otrexup’s patent estate is structurally narrower than the estate of a new chemical entity. Its strength depends on claim scope and design-around difficulty.

Protection layer	Relative strength
Methotrexate composition-of-matter patent	None of practical relevance
Basic aqueous methotrexate formulation	Limited
Specific concentration and pH range	Moderate if narrowly claimed
Autoinjector mechanism	Potentially strong if difficult to design around
Method of subcutaneous administration	Moderate, subject to claim scope
Device-formulation combination	Potentially strong
FDA exclusivity	Expired
Manufacturing know-how	Moderate trade-secret value

The strongest defensible position is likely a combination of device engineering, validated manufacturing processes, human-factors data, and commercial know-how. A competitor can often avoid a narrow formulation patent by using the same active ingredient with a different excipient ratio or device configuration.

What licensing opportunities exist around Otrexup?

The transaction history creates a clear commercial ownership path. Halozyme completed its acquisition of Antares Pharma in 2022 in a transaction valued at approximately $960 million.[3] Otrexup became part of Halozyme’s commercial and product portfolio.

Licensing opportunities could involve:

• Regional commercialization rights;
• A contract-manufacturing agreement for sterile fill-finish;
• Autoinjector licensing;
• Formulation or container-closure technology;
• Co-development of a lower-volume methotrexate product;
• Distribution partnerships with rheumatology specialty pharmacies.

The most valuable license would combine product rights with device and manufacturing rights. A license limited to the methotrexate formulation would have weaker strategic value because the active ingredient is generic and the excipient system is simple.

What manufacturing and IP barriers affect Otrexup competition?

Manufacturing barriers are higher than the excipient list suggests. A successful product requires:

• Sterile aqueous manufacturing;
• Low-volume fill-finish capability;
• Consistent methotrexate assay and impurity control;
• Autoinjector assembly;
• Device-component inspection;
• Container-closure integrity testing;
• Injection-force and delivery-time control;
• Human-factors validation;
• Combination-product quality systems.

The principal bottleneck is likely integrated device production rather than methotrexate synthesis. A company may have access to inexpensive methotrexate API but lack the capabilities required to manufacture and validate a reliable autoinjector.

Geographic protection will also vary. U.S. device patents may not control European, Canadian, or Asian launches. However, regulatory requirements for combination products, medical devices, pharmacovigilance, and self-administration can materially affect launch timing in each market.

What revenue exposure and commercial opportunities exist?

Otrexup’s revenue opportunity is tied to adherence, administration convenience, and specialty-pharmacy access. Methotrexate is widely used, but most patients do not require an autoinjector. The addressable segment is concentrated among patients who:

• Have difficulty using vials or syringes;
• Prefer home administration;
• Need subcutaneous dosing;
• Have inadequate response or intolerance to oral methotrexate;
• Require caregiver-assisted administration;
• Have insurance coverage for a branded device product.

Commercial growth can come from five areas:

1. Converting patients from oral methotrexate when clinically appropriate;
2. Converting patients from vial-based injectable methotrexate;
3. Expanding rheumatology specialty-pharmacy distribution;
4. Improving payer coverage through lower-cost presentations;
5. Licensing a device or formulation platform to regional partners.

A lower-cost autoinjector would have the greatest potential to expand the market, while a new excipient alone would probably have limited impact.

Key Takeaways

• Otrexup uses a simple preservative-free aqueous methotrexate formulation.
• Its identified excipients are sodium chloride, sodium hydroxide, hydrochloric acid, and water for injection.
• The product’s main commercial differentiation is the autoinjector, not the excipient system.
• FDA exclusivity expired after the three-year period associated with the 2013 approval.
• Patent risk is concentrated in device architecture, device-formulation combinations, and administration methods.
• The strongest follow-on opportunities are lower-volume injections, improved injection comfort, broader temperature stability, and lower-cost autoinjectors.
• Rasuvo is the closest branded competitor; vial-based generics create price pressure but are less directly substitutable.
• Halozyme acquired Antares Pharma in 2022, bringing Otrexup into Halozyme’s portfolio.
• Manufacturing complexity lies in sterile combination-product production and device validation rather than methotrexate API supply.
• A commercially successful challenger must combine formulation stability, device reliability, human-factors performance, payer access, and freedom to operate.

FAQs

Can Otrexup be reformulated with a preservative?

A preservative could be evaluated, but it would conflict with the current single-dose, preservative-free positioning and could create new tolerability, regulatory, and device-compatibility issues.

Is a higher-concentration Otrexup formulation commercially attractive?

Yes. A higher concentration could reduce injection volume and enable a smaller device, but methotrexate solubility, pH, local tolerability, and dose accuracy would determine feasibility.

Would a generic methotrexate vial directly replace Otrexup?

Not necessarily. A vial contains the same active ingredient but does not provide the same integrated autoinjector experience. Substitution depends on FDA approval, pharmacy rules, payer policy, and product labeling.

Could an Otrexup competitor use a different buffer?

Yes. A different buffer could support stability or injection comfort, but it would require formulation, compatibility, extractables-and-leachables, sterility, and stability validation.

What is the most attractive licensing asset related to Otrexup?

The most attractive asset is an integrated autoinjector and formulation package with validated methotrexate compatibility, manufacturing capability, and rights that avoid blocking device patents.

References

1. U.S. Food and Drug Administration. (2013). Otrexup (methotrexate injection) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Halozyme Therapeutics, Inc. (2022). Halozyme completes acquisition of Antares Pharma.